Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes
Mohit Sachdeva, … , Diana M. Cardona, David G. Kirsch
Mohit Sachdeva, … , Diana M. Cardona, David G. Kirsch
Published October 1, 2014; First published September 2, 2014
Citation Information: J Clin Invest. 2014;124(10):4305-4319. https://doi.org/10.1172/JCI77116.
View: Text | PDF | Corrigendum
Category: Research Article

MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

  • Text
  • PDF
Abstract

Metastasis causes most cancer deaths, but is incompletely understood. MicroRNAs can regulate metastasis, but it is not known whether a single miRNA can regulate metastasis in primary cancer models in vivo. We compared the expression of miRNAs in metastatic and nonmetastatic primary mouse sarcomas and found that microRNA-182 (miR-182) was markedly overexpressed in some tumors that metastasized to the lungs. By utilizing genetically engineered mice with either deletion of or overexpression of miR-182 in primary sarcomas, we discovered that deletion of miR-182 substantially decreased, while overexpression of miR-182 considerably increased, the rate of lung metastasis after amputation of the tumor-bearing limb. Additionally, deletion of miR-182 decreased circulating tumor cells (CTCs), while overexpression of miR-182 increased CTCs, suggesting that miR-182 regulates intravasation of cancer cells into the circulation. We identified 4 miR-182 targets that inhibit either the migration of tumor cells or the degradation of the extracellular matrix. Notably, restoration of any of these targets in isolation did not alter the metastatic potential of sarcoma cells injected orthotopically, but the simultaneous restoration of all 4 targets together substantially decreased the number of metastases. These results demonstrate that a single miRNA can regulate metastasis of primary tumors in vivo by coordinated regulation of multiple genes.

Authors

Mohit Sachdeva, Jeffrey K. Mito, Chang-Lung Lee, Minsi Zhang, Zhizhong Li, Rebecca D. Dodd, David Cason, Lixia Luo, Yan Ma, David Van Mater, Rebecca Gladdy, Dina C. Lev, Diana M. Cardona, David G. Kirsch

×

Figure 5

Deletion of miR-182 decreases intravasation of sarcoma cells into the circulation.

Options: View larger image (or click on image) Download as PowerPoint
Deletion of miR-182 decreases intravasation of sarcoma cells into the ci...
(A) Schematic showing the study design for isolation and analysis of YFP+ CTCs in the blood. (B) Flow cytometry reveals significantly lower number of YFP+ cells in both the blood and lung after miR-182 deletion. (C) No change in YFP+ cells in primary tumors between the 2 genotypes. (D and E) Quantification of CD45–YFP+ cells within the blood and the lungs between the 2 genotypes. (F) Images show the morphology of isolated YFP+ sarcoma cells from the blood. (G) PCR demonstrates that isolated CD45–YFP+ cells have successfully recombined LSL-Kras, deleted p53, and recombined LSL-YFP. TC, tumor cells. (H) Number of YFP+ cells in the blood correlates with the level of miR-182 in the primary sarcoma in KPY mice. Two-tailed Student’s t test and Fisher’s exact test were used for statistical analysis. All data are mean ± SEM. Scale bars: 100 μm.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts